AtriCure (NASDAQ:ATRC) Releases Earnings Results

23 Jul 2026, 21:44 by Mitch Edgeman · The Markets Daily

AtriCure (NASDAQ:ATRC – Get Free Report) released its quarterly earnings results on Thursday. The medical device company reported $0.18 EPS for the quarter, FiscalAI reports. The firm had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a negative net margin of 0.83% and a positive return on equity of 0.29%. AtriCure updated its FY 2026 guidance to 0.240-0.320 EPS.

AtriCure Trading Down 1.6%

NASDAQ ATRC traded down $0.52 on Thursday, hitting $33.00. The company’s stock had a trading volume of 1,130,784 shares, compared to its average volume of 784,313. The firm has a market cap of $1.67 billion, a P/E ratio of -330.00 and a beta of 1.24. AtriCure has a 52-week low of $25.36 and a 52-week high of $43.18. The company’s 50-day simple moving average is $29.81 and its 200 day simple moving average is $31.44. The company has a current ratio of 4.29, a quick ratio of 3.18 and a debt-to-equity ratio of 0.15.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ATRC shares. Weiss Ratings cut shares of AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday. Canaccord Genuity Group raised their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $49.12.

Read Our Latest Research Report on AtriCure

Insider Activity

In related news, Director Karen Prange sold 3,000 shares of AtriCure stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total transaction of $85,950.00. Following the completion of the transaction, the director directly owned 26,373 shares of the company’s stock, valued at $755,586.45. This trade represents a 10.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AtriCure

A number of hedge funds have recently bought and sold shares of ATRC. AQR Capital Management LLC lifted its stake in shares of AtriCure by 1.0% in the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after buying an additional 837 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of AtriCure by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after acquiring an additional 1,230 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after acquiring an additional 8,956 shares during the last quarter. Jane Street Group LLC lifted its position in AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after acquiring an additional 87,553 shares in the last quarter. Finally, Strs Ohio bought a new position in AtriCure in the 1st quarter valued at approximately $158,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.